SCHEMBL684525

SCHEMBL684525

O=C(N/N=C/c1cc(Br)ccc1O)c1ccc(Cl)cc1

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 10/20 0.85
KDM4E B2RXH2 9/20 0.85
MEN1 O00255 6/20 0.85
HTT P42858 6/20 0.85
RAB9A P51151 5/20 0.85
LMNA P02545 4/20 0.85
SMN1; SMN2 Q16637 4/20 0.85
POLB P06746 2/20 0.85
PSMD14 O00487 1/20 0.85
MMP2 P08253 1/20 0.85
BLM P54132 1/20 0.85
MAPT P10636 6/20 0.73
MITF O75030 4/20 0.73
NPC1 O15118 3/20 0.73
ASF1A Q9Y294 2/20 0.73
L3MBTL1 Q9Y468 2/20 0.73
TDP1 Q9NUW8 1/20 0.73
KDM1A O60341 2/20 0.72
ALOX12 P18054 1/20 0.66
KLF5 Q13887 2/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30122159 1.00 KMT2A (0.85) KMT2AKDM4EMEN1HTTRAB9A
SCHEMBL20446303 1.00 KMT2A (0.85) KMT2AKDM4EMEN1HTTRAB9A
SCHEMBL684542 0.92 KMT2A (1.00) KMT2AKDM4EMEN1HTTRAB9A
SCHEMBL19283336 0.89 KMT2A (0.76) KMT2AKDM4EMEN1HTTRAB9A
SCHEMBL19283338 0.89 KMT2A (0.76) KMT2AKDM4EMEN1HTTRAB9A
SCHEMBL6568342 0.89 KDM1A (0.89) KMT2AKDM4EMEN1HTTRAB9A
SCHEMBL683818 0.89 KDM1A (0.89) KMT2AKDM4EMEN1HTTRAB9A
SCHEMBL6568344 0.89 KDM1A (0.89) KMT2AKDM4EMEN1HTTRAB9A
SCHEMBL684944 0.87 ASF1A (0.74) KMT2AKDM4EMEN1HTTRAB9A
SCHEMBL6751411 0.86 KDM1A (0.85) KMT2AKDM4EMEN1HTTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210276984-A1 ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY ASTEX THERAPEUTICS LIMITED (GB) 2021-09-09 US disclosed
US-10981898-B2 Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity ASTEX THERAPEUTICS LIMITED (GB) 2021-04-20 US disclosed
US-20200247789-A2 ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY ASTEX THERAPEUCTICS LIMITED (GB) 2020-08-06 US disclosed
US-10544132-B2 Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity ASTEX THERAPEUTICS LIMITED (GB) 2020-01-28 US disclosed
US-20190016708-A1 ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY ASTEX THERAPEUTICS LIMITED (GB) 2019-01-17 US disclosed
US-20120010075-A1 SYNERGISTIC FUNGICIDAL COMPOSITIONS INCLUDING HYDRAZONE DERIVATIVES AND COPPER DOW AGROSCIENCES LLC (US) 2012-01-12 US disclosed
US-20120010075-A1 SYNERGISTIC FUNGICIDAL COMPOSITIONS INCLUDING HYDRAZONE DERIVATIVES AND COPPER DOW AGROSCIENCES LLC (US) 2012-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10544132-B2 Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity TP53, MDM2, TP53BP1 KMT2A 3047/4885KDM4E 3817/4885MEN1 1609/4885
US-20120010075-A1 SYNERGISTIC FUNGICIDAL COMPOSITIONS INCLUDING HYDRAZONE DERIVATIVES AND COPPER SOD1, CYP51A1, SOD3 KMT2A 1362/4885KDM4E 1473/4885MEN1 536/4885
US-10981898-B2 Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity TP53, MDM2, TP53BP1 KMT2A 3047/4885KDM4E 3817/4885MEN1 1609/4885
US-20190016708-A1 ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY TP53, MDM2, TP53BP1 KMT2A 3047/4885KDM4E 3817/4885MEN1 1609/4885
US-20210276984-A1 ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY TP53, MDM2, TP53BP1 KMT2A 3047/4885KDM4E 3817/4885MEN1 1609/4885
US-20200247789-A2 ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY TP53, MDM2, TP53BP1 KMT2A 3047/4885KDM4E 3817/4885MEN1 1609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.